Ligand Pharmaceuticals to Report Q4 and Full Year 2025 Results Amid Share Price Volatility

Ligand Pharmaceuticals will release its financial results for the fourth quarter and full year of 2025 on February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The announcement comes as the biopharmaceutical company navigates a period of share price volatility.

At a last close of $183.83, the company carries annual revenue of $251.233 million and net income of $48.581 million, supported by positive annual revenue and net income growth. The company had revenues of $162 million in Q3 2025, representing an increase of 94.02% from the same period in the prior year.

Recent share price performance has been mixed. The stock showed a 1 day gain of 1.2% but experienced a 30 day share price return of a 4.7% decline and a 90 day share price return of an 8.7% decline. This contrasts with a strong 1 year total shareholder return of 53.2%, suggesting earlier optimism is cooling rather than building further momentum. Longer term 3 year and 5 year total returns are reported at very large multiples relative to the starting point.

Ligand is a biopharmaceutical company focused on supporting the development of high-value medicines through financing and licensing technologies, while partnering with leading pharmaceutical companies to generate revenue. The company operates with two main technologies, Captisol® and NITRICIL™, aimed at improving drug solubility and stability, and enabling tunable dosing.

The company has established partnerships with leading companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International. The accelerating pace of R&D outsourcing and drug discovery innovation, along with increased regulatory support for differentiated, high-value products, positions Ligand as a key royalty and platform provider.

Institutional investor activity has been mixed in recent quarters. A total of 177 institutional investors added shares of the stock to their portfolio, while 137 decreased their positions in their most recent quarter. Notable moves included FMR LLC adding 431,008 shares, an increase of 1643.6%, to their portfolio in Q3 2025 for an estimated $76,348,757, while ACUITAS INVESTMENTS, LLC removed 402,494 shares, a 100% reduction, from their portfolio in Q4 2025 for an estimated $76,099,540.

Insider trading activity showed 36 transactions over the past 6 months, all of which were sales with no purchases recorded during that period.

The conference call can be accessed by dialing (800) 715-9871 for U.S. and Canada, or (646) 307-1963 internationally. The company carries a value score of 3, and the current P/E stands at 74.5x, which sits well above the US Pharmaceuticals average of 20.2x to 20.9x.